Hepatocellular Carcinoma

Current and Emerging Systemic Therapies for Hepatocellular Carcinoma: Clinical Evidence and Guideline Recommendations

The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with HCC.

Immunotherapy in Hepatocellular Carcinoma: Improving the Treatment Paradigm Within Community Practice

The goal of this program is to improve the knowledge and competence of learners to individualize the therapeutic management of patients with hepatocellular carcinoma (HCC).

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

Advances in Hepatocellular and Biliary Tract Cancers Impacting Patient Outcomes

The goal of this program is to improve the knowledge and competence of learners to individualize the therapeutic management of patients with hepatobiliary cancers.

New and Notable Clinical Data and Guideline Updates on Systemic Therapies in Hepatocellular Carcinoma

The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with hepatocellular carcinoma.

Collaborative Strategies to Ensure Optimal Application of the Latest Treatment Approaches in Hepatocellular Carcinoma (JA copy)

The goal of this activity is to improve participants’ competence in applying the latest treatment approaches and interdisciplinary collaborative strategies towards optimal care of patients with hepatocellular carcinoma.

Liver-Directed and Systemic Therapy Options for Hepatocellular Carcinoma

Incidence and mortality rates for most cancers are declining; however, the incidence and mortality rates for liver cancer are increasing. A thorough understanding of the different approaches to treatment can help clinicians identify the optimal treatment strategy. Keeping clinicians abreast of new developments in the field can better inform clinical decision-making.

Archived Monthly Oncology Tumor Boards: Update on New Treatments for Biliary Tract Cancers

While relatively rare, biliary tract cancers have a poor prognosis. Recently, molecular profiling has become increasingly useful as some new targeted therapies received FDA approval. It is important for clinicians to keep abreast of new and upcoming therapies in order to develop an optimal treatment strategy.

Monthly Oncology Tumor Boards: Update on New Treatments for Biliary Tract Cancers

While relatively rare, biliary tract cancers have a poor prognosis. Recently, molecular profiling has become increasingly useful as some new targeted therapies received FDA approval. It is important for clinicians to keep abreast of new and upcoming therapies in order to develop an optimal treatment strategy.

New Systemic Treatment Options for Hepatobiliary Cancers

In recent years, multiple treatment options were added for the first-line treatment of hepatocellular carcinoma as well as for first- and subsequent-line treatment of biliary tract cancers. As molecular profiling can help identify eligibility for more targeted clinical trials or therapies, physicians should consider gene testing. Knowledge of the new therapies will help better inform clinical decision-making.

Navigating a New Therapeutic Era for HCC: Expert Review of New Agents and Guideline Recommendations